Navigation Links
Dual Frost & Sullivan Accolade for Veolia Water Solutions & Technologies
Date:7/7/2009

LONDON, July 7 /PRNewswire/ -- Frost & Sullivan has conferred two prestigious awards on Veolia Water Solutions & Technologies (VWS). The "2008 Frost & Sullivan European Pharmaceutical Water & Wastewater Treatment Business Development Strategy Leadership Award," lauds VWS for its successful strategies that have enabled it to consolidate its position as one of the leading process water and wastewater solution providers for the pharmaceutical industry in Europe. The "2008 Frost & Sullivan CEO of the Year Award in the Global Water and Wastewater Treatment Technology Market" is presented to Jean Michel Herrewyn for his stellar role in steering this growth.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

"The success of VWS in the highly process critical pharmaceutical industry is attributed to its well structured business strategies that center on customised advanced treatment technologies and comprehensive, fully integrated treatment and service solutions," notes Frost & Sullivan Research Analyst Karthikeyan Ravikumar. "Superior product quality, coupled with effective after sales services, has resulted in high levels of customer satisfaction."

Since 2005, VWS has also been successful in offering turnkey solutions on a global basis to the pharmaceutical industry. High quality standard equipment offerings include ORION(TM), QUATTRO(TM), TRITON and POLARIS for producing Purified Water (PW) and Water for Injection (WFI). The company also offers two unique after sales services - AQUATREND(TM) and AQUAMOVE(TM). These have been focused on achieving high levels of customer service satisfaction.

With Jean Michel at the helm, the company has successfully shifted from a market segment-based approach (which involved the division of the water industry into three segments: municipal, industria
'/>"/>

SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. APAC Sensors Market Likely to be Driven by Medical and Process Industries in 2009, Says Frost & Sullivan
2. Multiple Advantages to Boost Deployment of Wireless and Handheld Devices in Healthcare, States Frost & Sullivan
3. Frost & Sullivan European Gastroenterology Technology Implementation of the Year Award Bestowed on Crospon
4. Cellular Technology Extends the Boundaries of E-healthcare, Says Frost & Sullivan
5. Growing Proteomics Market and the Current Economic Crisis Could Act in Tandem to Spur Growth in the European 2 Dimensional Gel Electrophoresis Market, States Frost & Sullivan
6. Hospital Information Systems (HIS) Markets in Europe: Frost & Sullivan Reveals the Cost, Crunch and the Care Value
7. Pulse Oximetry Entrenched as Standard-of-Care in Patient Monitoring, States Frost & Sullivan
8. Frost & Sullivan: Self-Monitoring and POC Diabetes Tests Reveal Potential for Significant Growth, Boosting the European Diabetes Diagnostics Market
9. Frost & Sullivan Selects Bone Solutions for Technology Leadership of the Year Award
10. Frost & Sullivan Sees Opportunities in Chinese Vaccine Industry
11. Digital Mammography and Clinical Review Display Units Energising the European Markets for Medical Imaging Display Monitors, Finds Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:RetireSafe Announces Intention to Key Vote Senator Dorgan's Drug Importation Amendment (SA 2793) 2Hand Surgeons Take Ethics into Their Own Hands 2Hand Surgeons Take Ethics into Their Own Hands 3Hand Surgeons Take Ethics into Their Own Hands 4DecisionView Launches StudyOptimizer(TM) 4 2DecisionView Launches StudyOptimizer(TM) 4 3Transave Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections 5556 1Transave Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections 5556 2Transave Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections 5556 3Transave Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections 5556 4Transave Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections 5556 5Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr Robert Garnick as Head of Regulatory Affairs 5551 1Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr Robert Garnick as Head of Regulatory Affairs 5551 2Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr Robert Garnick as Head of Regulatory Affairs 5551 3Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr Robert Garnick as Head of Regulatory Affairs 5551 4Hangovers May Be Tougher for Migraine Sufferers 59737 1